What Is Continuous Glucose Monitor

A continuous glucose monitor (CGM) is a small wearable device that measures glucose levels in the interstitial fluid beneath the skin, typically sampling every one to five minutes. It produces a continuous stream of data rather than the single snapshot provided by a finger-prick blood glucose test. The resulting graph reveals how meals, movement, sleep, and stress shape blood sugar patterns across the full 24-hour cycle.

Glucose regulation sits at the center of metabolic health, and metabolic dysfunction is among the strongest predictors of chronic disease and accelerated aging. Sustained hyperglycemia, repeated glucose spikes, and insulin resistance contribute to glycation of proteins, vascular damage, chronic inflammation, and mitochondrial stress. These processes drive the development of cardiovascular disease, neurodegeneration, kidney damage, and other conditions that shorten both lifespan and healthspan.

Traditional metabolic testing, such as fasting glucose or HbA1c, captures averages and single moments. A CGM, by contrast, shows the full dynamic picture: how high glucose rises after a particular meal, how quickly it returns to baseline, and whether overnight levels remain stable. This granularity allows individuals to identify specific dietary and lifestyle triggers well before conventional markers register a problem, creating an opportunity for earlier intervention.

The core component of a CGM is a flexible electrochemical sensor, typically a thin filament about 5 to 7 millimeters long, inserted into the subcutaneous tissue using a spring-loaded applicator. This filament is coated with glucose oxidase, an enzyme that reacts with glucose in the interstitial fluid. As glucose molecules interact with the enzyme, a small electrical current is generated proportional to the glucose concentration. A transmitter attached to the skin surface reads this current and converts it to a glucose value, sending the data wirelessly to a paired device.

Interstitial glucose lags behind blood glucose by roughly 5 to 15 minutes because glucose must diffuse from capillaries into the surrounding tissue fluid. Modern algorithms partially correct for this lag, but users should be aware that CGM readings during rapidly changing glucose (for example, immediately after consuming sugar) may not perfectly match a simultaneous finger-prick reading. Most systems require an initial calibration period of 30 to 60 minutes after insertion before they begin reporting data.

The data is displayed as a trend line, often with overlays for meals, exercise, and sleep. Many platforms also calculate summary statistics such as time in range (the percentage of readings between roughly 70 and 140 mg/dL), average glucose, glucose variability (expressed as standard deviation or coefficient of variation), and the number and magnitude of spikes. These metrics collectively give a far richer metabolic portrait than any single lab value.

A CGM measures glucose concentration in the interstitial fluid, the thin layer of liquid that bathes the cells just beneath the skin. This is not identical to blood glucose, but it closely tracks it with a short time lag. The sensor samples every one to five minutes depending on the device, producing up to 288 or more data points per day.

From this raw stream, most CGM platforms calculate several derived metrics. Time in range quantifies the percentage of the day spent within a target glucose window, commonly 70 to 140 mg/dL for non-diabetic users. Average glucose provides a mean value analogous to what HbA1c reflects over three months, but with daily or weekly granularity. Glucose variability, often expressed as coefficient of variation, captures how much blood sugar fluctuates. Together, these metrics characterize metabolic stability far more comprehensively than any single fasting blood draw.

Preparation for wearing a CGM is straightforward. The sensor is typically applied to the back of the upper arm or the abdomen using a single-use applicator that inserts the filament and adheres the transmitter in one motion. Cleaning the skin with an alcohol swab and allowing it to dry before application improves adhesion and reduces infection risk. Some people find that applying a skin-barrier wipe or over-patch improves sensor longevity, especially during heavy sweating or swimming.

For the data to be useful, plan to log meals, exercise, and sleep with reasonable consistency during the wear period. Many companion apps allow photo-based meal logging or integration with food databases. Aim to eat a few "challenge meals" that include foods you eat regularly so you can observe your individual responses. There is no need to fast before application, and no dietary restriction is required during wear.

The most informative way to read CGM data is to focus on three patterns. First, look at postprandial responses: how high does glucose rise after each meal, and how long before it returns to baseline? A rise of more than roughly 30 to 40 mg/dL from pre-meal levels, or a return time exceeding two hours, suggests a strong glycemic response to that meal composition or portion size. Second, examine fasting and overnight glucose. Consistently elevated fasting glucose (above 100 mg/dL) or a rising overnight trend may indicate early insulin resistance or the influence of cortisol and stress hormones.

Third, assess overall variability. A coefficient of variation below 20 to 25 percent and time in range above 85 to 90 percent are commonly cited targets for non-diabetic individuals seeking metabolic optimization, though these thresholds derive from expert opinion rather than hard outcome data. Context matters: a glucose spike during vigorous exercise reflects normal physiology, not a problem. Interpreting CGM data well requires looking at the full day in context rather than reacting to isolated readings.

For most non-diabetic individuals, continuous wear is not necessary after an initial learning phase. A practical approach is to wear a CGM for two to four weeks during a focused observation period, then remove it and apply what you have learned. Periodic re-testing, perhaps two weeks every three to six months, can confirm that your dietary and lifestyle patterns continue to produce stable glucose responses, or reveal whether changes in sleep, stress, fitness, or body composition have shifted your metabolic baseline.

People managing prediabetes, insulin resistance, or active metabolic conditions may benefit from longer or more frequent wear periods to track the effects of dietary interventions, exercise programs, or medications. For individuals with type 1 or type 2 diabetes, continuous wear is standard clinical practice, as it enables real-time insulin dosing decisions and safety alerts for hypo- and hyperglycemia.

CGM technology has a substantial evidence base in diabetes management. Multiple randomized controlled trials have demonstrated that CGM use improves HbA1c, increases time in range, and reduces hypoglycemic episodes in people with type 1 and type 2 diabetes. The technology's accuracy has improved significantly across device generations, with current models showing mean absolute relative differences (a standard accuracy metric) in the range of 9 to 12 percent compared to laboratory venous glucose.

The evidence for CGM use in people without diabetes is less mature. Observational studies and smaller trials have shown that CGM-guided dietary changes can reduce glucose variability and postprandial spikes in non-diabetic populations, but long-term outcome data linking CGM use in healthy individuals to reduced disease incidence or extended lifespan do not yet exist. Epidemiological research consistently associates high glucose variability with cardiovascular risk and mortality, providing a plausible rationale for minimizing it, but the causal chain from CGM use to improved hard outcomes in metabolically healthy people remains unproven. The field is actively accumulating data, and several longer-term trials are underway.

The physical risks of CGM use are minor: skin irritation or adhesive allergy at the application site, occasional inaccurate readings during rapid glucose changes, and rare bruising at insertion. The more significant concern is behavioral. Continuous biometric feedback can generate anxiety, orthorexic tendencies, or an unhealthy preoccupation with numerical optimization, particularly in individuals prone to perfectionism or eating disorders. CGM readings should be interpreted as patterns over days, not as moment-to-moment commands. It is also worth noting that interstitial glucose is a proxy for blood glucose, not a direct equivalent, and clinical decisions (especially medication adjustments) should not be based on CGM data alone without appropriate clinical guidance.